134 related articles for article (PubMed ID: 37864955)
1. AXL - a new player in resistance to HER2 blockade.
Adam-Artigues A; Arenas EJ; Arribas J; Prat A; Cejalvo JM
Cancer Treat Rev; 2023 Dec; 121():102639. PubMed ID: 37864955
[TBL] [Abstract][Full Text] [Related]
2. Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer.
Adam-Artigues A; Arenas EJ; Martínez-Sabadell A; Brasó-Maristany F; Cervera R; Tormo E; Hernando C; Martínez MT; Carbonell-Asins J; Simón S; Poveda J; Moragón S; Zazo S; Martínez D; Rovira A; Burgués O; Rojo F; Albanell J; Bermejo B; Lluch A; Prat A; Arribas J; Eroles P; Cejalvo JM
Sci Adv; 2022 May; 8(20):eabk2746. PubMed ID: 35594351
[TBL] [Abstract][Full Text] [Related]
3. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL.
Liu L; Greger J; Shi H; Liu Y; Greshock J; Annan R; Halsey W; Sathe GM; Martin AM; Gilmer TM
Cancer Res; 2009 Sep; 69(17):6871-8. PubMed ID: 19671800
[TBL] [Abstract][Full Text] [Related]
4. Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to Therapy.
Scaltriti M; Elkabets M; Baselga J
Clin Cancer Res; 2016 Mar; 22(6):1313-7. PubMed ID: 26763248
[TBL] [Abstract][Full Text] [Related]
5. Activation of HER3 interferes with antitumor effects of Axl receptor tyrosine kinase inhibitors: suggestion of combination therapy.
Torka R; Pénzes K; Gusenbauer S; Baumann C; Szabadkai I; Őrfi L; Kéri G; Ullrich A
Neoplasia; 2014 Apr; 16(4):301-18. PubMed ID: 24862757
[TBL] [Abstract][Full Text] [Related]
6. AXL/WRNIP1 Mediates Replication Stress Response and Promotes Therapy Resistance and Metachronous Metastasis in HER2+ Breast Cancer.
Marquez-Palencia M; Reza Herrera L; Parida PK; Ghosh S; Kim K; Das NM; Gonzalez-Ericsson PI; Sanders ME; Mobley BC; Diegeler S; Aguilera TA; Peng Y; Lewis CM; Arteaga CL; Hanker AB; Whitehurst AW; Lorens JB; Brekken RA; Davis AJ; Malladi S
Cancer Res; 2024 Mar; 84(5):675-687. PubMed ID: 38190717
[TBL] [Abstract][Full Text] [Related]
7. Targeting Axl favors an antitumorigenic microenvironment that enhances immunotherapy responses by decreasing Hif-1α levels.
Goyette MA; Elkholi IE; Apcher C; Kuasne H; Rothlin CV; Muller WJ; Richard DE; Park M; Gratton JP; Côté JF
Proc Natl Acad Sci U S A; 2021 Jul; 118(29):. PubMed ID: 34266948
[TBL] [Abstract][Full Text] [Related]
8. The Receptor Tyrosine Kinase AXL Is Required at Multiple Steps of the Metastatic Cascade during HER2-Positive Breast Cancer Progression.
Goyette MA; Duhamel S; Aubert L; Pelletier A; Savage P; Thibault MP; Johnson RM; Carmeliet P; Basik M; Gaboury L; Muller WJ; Park M; Roux PP; Gratton JP; Côté JF
Cell Rep; 2018 May; 23(5):1476-1490. PubMed ID: 29719259
[TBL] [Abstract][Full Text] [Related]
9. AXL Receptor in Breast Cancer: Molecular Involvement and Therapeutic Limitations.
Falcone I; Conciatori F; Bazzichetto C; Bria E; Carbognin L; Malaguti P; Ferretti G; Cognetti F; Milella M; Ciuffreda L
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33182542
[TBL] [Abstract][Full Text] [Related]
10. MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents.
McDaniel NK; Cummings CT; Iida M; Hülse J; Pearson HE; Vasileiadi E; Parker RE; Orbuch RA; Ondracek OJ; Welke NB; Kang GH; Davies KD; Wang X; Frye SV; Earp HS; Harari PM; Kimple RJ; DeRyckere D; Graham DK; Wheeler DL
Mol Cancer Ther; 2018 Nov; 17(11):2297-2308. PubMed ID: 30093568
[TBL] [Abstract][Full Text] [Related]
11. Axl as a downstream effector of TGF-β1 via PI3K/Akt-PAK1 signaling pathway promotes tumor invasion and chemoresistance in breast carcinoma.
Li Y; Jia L; Liu C; Gong Y; Ren D; Wang N; Zhang X; Zhao Y
Tumour Biol; 2015 Feb; 36(2):1115-27. PubMed ID: 25327287
[TBL] [Abstract][Full Text] [Related]
12. Giving AXL the axe: targeting AXL in human malignancy.
Gay CM; Balaji K; Byers LA
Br J Cancer; 2017 Feb; 116(4):415-423. PubMed ID: 28072762
[TBL] [Abstract][Full Text] [Related]
13. YAP-Dependent AXL Overexpression Mediates Resistance to EGFR Inhibitors in NSCLC.
Ghiso E; Migliore C; Ciciriello V; Morando E; Petrelli A; Corso S; De Luca E; Gatti G; Volante M; Giordano S
Neoplasia; 2017 Dec; 19(12):1012-1021. PubMed ID: 29136529
[TBL] [Abstract][Full Text] [Related]
14. AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer.
Dunne PD; McArt DG; Blayney JK; Kalimutho M; Greer S; Wang T; Srivastava S; Ong CW; Arthur K; Loughrey M; Redmond K; Longley DB; Salto-Tellez M; Johnston PG; Van Schaeybroeck S
Clin Cancer Res; 2014 Jan; 20(1):164-75. PubMed ID: 24170546
[TBL] [Abstract][Full Text] [Related]
15. The AXL receptor tyrosine kinase is associated with adverse prognosis and distant metastasis in esophageal squamous cell carcinoma.
Hsieh MS; Yang PW; Wong LF; Lee JM
Oncotarget; 2016 Jun; 7(24):36956-36970. PubMed ID: 27172793
[TBL] [Abstract][Full Text] [Related]
16. Key Roles of AXL and MER Receptor Tyrosine Kinases in Resistance to Multiple Anticancer Therapies.
Schoumacher M; Burbridge M
Curr Oncol Rep; 2017 Mar; 19(3):19. PubMed ID: 28251492
[TBL] [Abstract][Full Text] [Related]
17. TAM family receptors in conjunction with MAPK signalling are involved in acquired resistance to PI3Kα inhibition in head and neck squamous cell carcinoma.
Ruicci KM; Meens J; Plantinga P; Stecho W; Pinto N; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Howlett CJ; Boutros PC; Ailles L; Nichols AC
J Exp Clin Cancer Res; 2020 Oct; 39(1):217. PubMed ID: 33059733
[TBL] [Abstract][Full Text] [Related]
18. Axl mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib.
Giles KM; Kalinowski FC; Candy PA; Epis MR; Zhang PM; Redfern AD; Stuart LM; Goodall GJ; Leedman PJ
Mol Cancer Ther; 2013 Nov; 12(11):2541-58. PubMed ID: 24026012
[TBL] [Abstract][Full Text] [Related]
19. Gas6/Axl Axis Contributes to Chemoresistance and Metastasis in Breast Cancer through Akt/GSK-3β/β-catenin Signaling.
Wang C; Jin H; Wang N; Fan S; Wang Y; Zhang Y; Wei L; Tao X; Gu D; Zhao F; Fang J; Yao M; Qin W
Theranostics; 2016; 6(8):1205-19. PubMed ID: 27279912
[TBL] [Abstract][Full Text] [Related]
20. The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells.
Meyer AS; Miller MA; Gertler FB; Lauffenburger DA
Sci Signal; 2013 Aug; 6(287):ra66. PubMed ID: 23921085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
